Regeneron Pharmaceuticals (REGN) and Sanofi (SNY) presented results from the DISCOVER Phase 4, single-arm, open-label trial assessing Dupixent in ...

Wall Street gains as S&P 500 surpasses 6,000; key healthcare stock movers revealed. Explore top deals, trends, and regulatory updates in the sector.

MarioGuti Most major stock indexes across the globe ended the week higher, as renewed optimism around US-China trade talks ...

Paris: Sanofi's global employee shareholder plan, Action 2025, opens on June 10, 2025, to around 70,000 employees in 55 ...

Pomerantz LLP is investigating claims on behalf of investors of Sanofi ("Sanofi" or the "Company") (NASDAQ: SNY).

Results for IRAKLIA show noninferiority for Sanofi's on-body delivery system for isatuximab, compared with IV administration.

Sanofi (NASDAQ:SNY)’s shares fell 5% this week, even as the company announced positive results from its AERIFY-1 trial with ...

Sanofi picked up Blueprint Medicines in a deal worth up to $9.5 billion. Bristol Myers Squibb will pay $1.5 billion upfront ...

The acquisition includes a rare immunology disease medicine and an advanced and early-stage immunology pipeline.

When an RSV vaccine became available for use during pregnancy, it offered a natural experiment between various countries to ...

The investment includes a significant boost to research and development and the expansion of partnerships with domestic ...

DEPARTMENT OF JUSTICE NEWS RELEASE Attorney General Raúl Torrez announced settlements with two major insulin ...